NeuroOne Featured on The Medical Alley Podcast: "A Conversation with Dave Rosa, President and CEO, NeuroOne"

EDEN PRAIRIE, Minn., Dec. 20, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, was featured on The Medical Alley Podcast, in an episode titled "A Conversation with Dave Rosa, President and CEO, NeuroOne."

Episode Summary:

"Join us for a conversation with Frank Jaskluke and Dave Rosa, President and CEO of NeuroOne Medical Technologies Corporation. Dave shares more about the innovation happening at NeuroOne, which develops thin high-definition film electrodes that can be used for numerous neurological conditions including epilepsy."

The episode is also available across podcast platforms including Medical Alley, Apple, and Spotify:

Medical Alley: https://medicalalleypodcast.org/episodes/a-conversation-with-dave-rosa-president-and-ceo-neuroone

Apple: https://podcasts.apple.com/us/podcast/a-conversation-with-dave-rosa-president-and-ceo-neuroone/id1523342401?i=1000544800983 

Spotify:https://open.spotify.com/episode/1Q8I0J1jLgGTWKeEvpmQjK?si=Gi1BTJkzRMyTPaEj_DUbvg 

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .

Forward Looking Statements

The podcast may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions, the impact of general economic, industry or political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of the podcast and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

SOURCE NeuroOne Medical Technologies Corporation